COST-EFFECTIVENESS ANALYSIS OF TREATMENT WITH ABOBOTULINUMTOXINA COMPARED TO BEST SUPPORTIVE CARE IN PATIENTS WITH UPPER LIMB SPASTICITY IN SWEDEN

被引：0
|
作者：
Forsmark, A. [1 ]
Danchenko, N. [2 ]
Ertzgaard, P. [3 ]
Lundkvist, J. [4 ]
Rosengren, L. [5 ]
机构：
[1] Nord Hlth Econ, Gothenburg, Sweden
[2] Ipsen Pharma, Boulogne, France
[3] Linkoping Univ, Fac Hlth Sci, Linkoping, Sweden
[4] Ipsen Pharma, Uppsala, Sweden
[5] Ipsen Pharma, Kista, Sweden
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2024
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND58
引用
收藏
页码：S338 / S339
页数：3
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment
    N Starling
    D Tilden
    J White
    D Cunningham
    British Journal of Cancer, 2007, 96 : 206 - 212
  • [32] THE COST-EFFECTIVENESS OF PALIPERIDONE PALMITATE COMPARED TO OLANZAPINE PAMOATE IN THE TREATMENT OF SCHIZOPHRENIA IN SWEDEN
    Pudas, H.
    Hemels, M.
    Mehnert, A.
    Druais, S.
    Martin, M.
    VALUE IN HEALTH, 2011, 14 (07) : A560 - A561
  • [33] Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States
    Ramjee, Lauren
    Vurgun, Nesrin
    Ngai, Christopher
    Patel, Mit
    Tremblay, Gabriel
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2023, 15 : 213 - 226
  • [34] Cost-effectiveness analysis of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone as first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma
    Han, Jiaqi
    Lan, Xiaomeng
    Tian, Kun
    Shen, Xi
    He, Jinlan
    Chen, Nianyong
    FRONTIERS IN PUBLIC HEALTH, 2023, 10
  • [35] COST-EFFECTIVENESS OF ORAL TOPOTECAN PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE IN PATIENTS WITH RELAPSED SMALL-CELL LUNG CANCER (SCLC) IN THE UK
    Lykopoulos, K.
    Morris, S.
    Papo, N.
    O'Brien, M. E.
    VALUE IN HEALTH, 2008, 11 (06) : A482 - A482
  • [36] Cost-effectiveness of oral topotecan plus best supportive care versus best supportive care alone in patients with relapsed small-cell lung cancer (SCLC) in the UK
    O'Brien, Mary E.
    Morris, Stephen
    Papo, Natalie L.
    Lykopoulos, Konstantinos
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S818 - S818
  • [37] Costs of Psychotic Disorders and Cost-effectiveness of Cognitive Behavioural Therapy Compared to Supportive Treatment
    Konnopka, Alexander
    Stuhldreher, Nina
    Klingberg, Stefan
    Wittorf, Andreas
    Bechdolf, Andreas
    Mueller, Bernhard
    Wagner, Michael
    Wiedemann, Georg
    Woelwer, Wolfgang
    Sartory, Gudrun
    Koenig, Hans-Helmut
    JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2013, 16 : S19 - S19
  • [38] COST-EFFECTIVENESS OF OCTREOTIDE COMPARED WITH USUAL SUPPORTIVE THERAPY FOR THE TREATMENT OF NEUROENDOCRINE TUMORS IN COLOMBIA
    Ruiz, A.
    Alfonso-Cristancho, R.
    Mejia, A.
    Gonzalez, D.
    Maestre, K.
    Herran, S.
    VALUE IN HEALTH, 2011, 14 (07) : A543 - A543
  • [39] COST-EFFECTIVENESS OF TREATING ROMANIAN POST-STROKE PATIENTS WITH UPPER LIMB SPASTICITY WITH INCOBOTULINUMTOXIN-A AGAINST CONVENTIONAL THERAPY
    Turcu-Stiolica, A.
    Subtirelu, M.
    VALUE IN HEALTH, 2018, 21 : S206 - S207
  • [40] Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma
    Xie, Qian
    Zheng, Hanrui
    Chen, Ye
    Peng, Xingchen
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
12345